NICE blocks diabetes drug despite approval in Scotland

Patients in England stand to miss out on a new class of diabetes treatment that is already available in Scotland, after NICE rejected the drug in a preliminary ruling.

NICE said there was 'significant uncertainty' about the manufacturers' trial results
NICE said there was 'significant uncertainty' about the manufacturers' trial results

Dapagliflozin (Forxiga) launched in the UK late last year and was approved by the Scottish Medicines Consortium in January as an add-on therapy with metformin.

However, NICE said it was unable to recommend the treatment in combination with insulin due to 'significant uncertainty' about results presented by the manufacturers, Bristol-Myers Squibb and AstraZeneca.

The institute has asked for further information on cost-effectiveness from the companies ahead of a further meeting about the drug in April.

Professor Carole Longson, director of NICE's health technology evaluation centre, said: 'Type 2 diabetes is a serious problem in the UK and it is important that there is a range of different treatment options available. Unfortunately, the appraisal committee is currently unable to recommend dapagliflozin, one of the options, for the treatment of this condition.'

Amadou Diarra, vice president and general manager UK and Ireland at Bristol Myers-Squibb, said: 'Bristol-Myers Squibb and AstraZeneca are disappointed with the outcome today, particularly given the alliance responded in full to the questions raised prior to the appraisal committee meeting. We submitted a robust dossier of information, which included an externally-validated cost-effectiveness model.'

The companies said they will provide additional information and analysis on the cost-effectiveness model to NICE.

Dapagliflozin is a new type of diabetes treatment class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. The oral, once-daily drug works by reducing the amount of glucose reabsorbed by the kidney and increasing glucose excretion in urine.

Research had shown the drug can reduce blood glucose by a similar amount as sulphoylurea plus metformin, and can also encourage weight loss.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Practices handed one-month opt-out window as revamped network DES unveiled

Practices handed one-month opt-out window as revamped network DES unveiled

NHS England has unveiled a revamped DES package for 2020/21 confirming new targets,...

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...